Healthcare Industry News: HSMN NewsFeed

Regenerative Medicine Wound Care Personnel

 News Release - January 25, 2019

Medical-Fish-Skin Company Kerecis Hires Stephen DiBiasio as Executive Vice President

ARLINGTON, Va., Jan. 25, 2019 -- (Healthcare Sales & Marketing Network) -- Industry veteran Stephen DiBiasio is the new executive vice president of Kerecis, the company pioneering the use of intact fish skin for the regeneration of human wounds and tissue damage. In this newly created position, DiBiasio will be responsible for the company's direct sales of the Kerecis Omega3 Wound and Kerecis Omega3 Burn products to healthcare facilities in the U.S. He will also be orchestrating the company's ambitious sales expansion plan.

"Stephen is an experienced life sciences and healthcare executive, with a proven track record of bringing disruptive technologies into the mainstream and making them successful," said G. Fertram Sigurjonsson, president and CEO of Kerecis. "Sales of our intact fish-skin wound treatment-product tripled last year. We are confident Stephen will build on that momentum and dramatically increase demand for our wound and burn products nationwide."

Most recently, DiBiasio was vice president of sales at SteadMed Medical, now Urgo Medical North America. DiBiasio helped start SteadMed with its founder, Michael Steadman, in 2011, and built it into a world-class organization with top-market-share positions in the wound-care industry. He was instrumental in positioning the company for a successful merger with Urgo Medical, the number-two wound-care player in Europe.

Before that, DiBiasio worked at industry giant Smith & Nephew for almost 17 years, where he was responsible for a $90 million+ business unit with more than 90 direct employees.

In his new position, DiBiasio will report directly to G. Fertram Sigurjonsson, president and CEO of Kerecis.

About Kerecis

Kerecis is pioneering the use of fish skin and fatty acids in the globally expanding market for cellular therapy and regenerative medicine. The fatty-acid-rich products from the company's patented technologies enable the body to regenerate tissues, rather than simply repair them and risk scarring. The Kerecis products, which are based on Omega3-rich intact fish skin, are currently being used to regenerate tissue in trauma and chronic wounds such as burns and diabetic wounds. Kerecis is also developing products for areas such as oral surgery, plastic surgery and neurological applications. The company's mission is to support the body's ability to regenerate tissues, and its vision is to become a world leader in tissue regeneration. For more information, visit www.kerecis.com.

Kerecis is a trademark of Kerecis.


Source: Kerecis

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.